Medtronic reported strong second-quarter results with higher sales and profits compared to last year. The company raised its revenue and earnings guidance for the coming periods, fueling a stock rally that has seen shares climb nearly 31% year-to-date and reach a 52-week high. Management highlighted a renewed focus on strategic tuck-in acquisitions in high-growth cardiology and neuroscience segments and investments in near-market technologies. The stock's relative strength rating was upgraded, indicating strong market accumulation and bullish momentum.